<DOC>
	<DOCNO>NCT00618657</DOCNO>
	<brief_summary>This phase II study side effect well carboplatin paclitaxel albumin-stabilized nanoparticle formulation together bevacizumab trastuzumab surgery work treat patient stage I-III breast cancer . Drugs use chemotherapy , carboplatin paclitaxel albumin-stabilized nanoparticle formulation , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab trastuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving one drug ( combination chemotherapy ) monoclonal antibody therapy together surgery may make tumor small reduce amount normal tissue need remove .</brief_summary>
	<brief_title>Carboplatin+Nab-paclitaxel , Plus Trastuzumab ( HER2+ ) Bevacizumab ( HER2- ) Neoadjuvant Setting</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate 2 year progression-free survival patient breast cancer 1 cm and/or lymph node positive breast cancer treat weekly Carboplatin/Nab-Paclitaxel ( trastuzumab patient HER2+ disease , bevacizumab HER2- ) . II . To measure clinical response rate patient treat neoadjuvant setting . III . To measure microscopic pathological response rate regimen patient treat neoadjuvant setting . IV . To measure toxicity deliver dose intensity regimen . V. To assess association microscopic pathologic complete response clinical complete response primary tumor site patient . VI . To measure outcome patient treat doxorubicin cyclophosphamide patient treat doxorubicin cyclophosphamide . SECONDARY OBJECTIVES : I . Develop quantitative analysis method obtain pre-treatment tumor characteristic morphological , enhancement kinetic , Choline metabolic parameter breast cancer . Select optimal set feature use logistic regression analysis Artificial Neural Network ( ANN ) predict pathologic complete remission ( pCR ) HER-2 positive negative arm . II . Investigate whether early response pattern , analyze use percent tumor size change , change lesion characteristic parameter , use predict pathologic complete remission ( pCR ) HER-2 positive negative arm . III . Investigate whether combine pre-treatment tumor characteristic parameter , early response pattern treatment course , achieve high `` area receiver operate characteristic ( ROC ) curve '' ( AUC ) prediction pCR base pre-treatment MRI characteristic tumor response pattern alone . OUTLINE : Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV 30 minute carboplatin IV 60 minute weekly 12 week . Patients HER2-positive disease receive trastuzumab IV 30-90 minute weekly 12 week patient HER2-negative disease receive bevacizumab IV 30-90 minute every two week 5 dos . Treatment continue absence disease progression unacceptable toxicity . Beginning 21-40 day later , patient undergo surgery . After completion study treatment , patient follow 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must woman histologically confirm diagnosis breast cancer 1 cm lymph node positive Physical examination , scan need tumor assessment must perform within 90 day prior registration Patients clinical diagnosis congestive heart failure angina pectoris NOT eligible Serum creatinine within normal limit within 90 day prior registration Bilirubin within normal limit within 90 day prior registration Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamate pyruvate transaminase ( SGPT ) = &lt; 2 x institutional upper limit normal within 90 day prior registration Absolute neutrophil count ( ANC ) &gt; = 1,500/microliters within 90 day prior registration Platelet count &gt; = 100,000/microliters within 90 day prior registration Patients must performance status 02 Zubrod criterion Pregnant nursing woman may participate ; woman reproductive potential may participate unless agree use effective contraceptive method ; pregnancy test require woman childbearing potential In calculate day test measurement , day test measurement do consider day 0 ; therefore , test do Monday , Monday four week later would consider day 28 ; allows efficient patient scheduling without exceed guideline ; day 28 42 fall weekend holiday , limit may extend next working day All patient must inform investigational nature study must sign give write informed consent accordance institutional federal guideline</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>pre-operative</keyword>
	<keyword>neo-adjuvant</keyword>
	<keyword>triple negative</keyword>
	<keyword>HER2 positive</keyword>
	<keyword>hormone receptor positive</keyword>
	<keyword>breast</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Nab-paclitaxel</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Inflammatory</keyword>
</DOC>